APLT RSI Chart
Last 7 days
-4.8%
Last 30 days
-13.5%
Last 90 days
-22.3%
Trailing 12 Months
176.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 10.0M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 12, 2024 | hooks corwin dale | acquired | - | - | 300,000 | chief commercial officer |
Mar 14, 2024 | shendelman shoshana | sold | -1,717,110 | 5.39 | -318,573 | president and ceo |
Mar 14, 2024 | perfetti riccardo | sold | -597,234 | 5.39 | -110,804 | chief medical officer |
Mar 14, 2024 | funtleyder leslie d. | sold | -154,839 | 5.39 | -28,727 | chief financial officer |
Mar 14, 2024 | hansard adam | sold | -263,415 | 5.39 | -48,871 | chief commercial officer |
Dec 28, 2023 | chinoporos constantine | acquired | - | - | 300,000 | see remarks |
Dec 21, 2023 | hansard adam | acquired | - | - | 400,000 | chief commercial officer |
Dec 21, 2023 | perfetti riccardo | acquired | - | - | 450,000 | chief medical officer |
Dec 21, 2023 | shendelman shoshana | acquired | - | - | 1,540,000 | president and ceo |
Dec 01, 2023 | kanter stacy j. | bought | 65,367 | 2.1789 | 30,000 | - |
Which funds bought or sold APLT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Artal Group S.A. | new | - | 6,864,600 | 6,864,600 | 0.17% |
May 16, 2024 | COMERICA BANK | unchanged | - | 6,900 | 13,600 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | added | 85.44 | 1,221,480 | 1,663,360 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | added | 54.39 | 4,289,560 | 6,299,690 | -% |
May 15, 2024 | J. Goldman & Co LP | new | - | 995,466 | 995,466 | 0.03% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | sold off | -100 | -62,601 | - | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | reduced | -10.32 | 532,610 | 1,181,840 | 0.02% |
May 15, 2024 | ADAGE CAPITAL PARTNERS GP, L.L.C. | new | - | 18,018,500 | 18,018,500 | 0.03% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | reduced | -45.75 | 96,984 | 1,055,070 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -95.99 | -238,859 | 21,141 | -% |
Unveiling Applied Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Applied Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Applied Therapeutics Inc News
Income Statement (Quarterly) | ||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 |
Revenue | - | - | - | - | - | 10,660 |
Operating Expenses | 4.6% | 21,283 | 20,340 | 15,495 | 17,176 | 21,518 |
S&GA Expenses | -100.0% | - | 5,038 | 4,710 | 5,293 | 5,583 |
R&D Expenses | -20.2% | 12,217 | 15,303 | 10,785 | 11,883 | 15,935 |
Net Income | -122.8% | -83,938 | -37,679 | -42,370 | -29,577 | -10,137 |
Net Income Margin | -61.6% | -19.37* | -11.98* | - | - | - |
Free Cashflow | -11.2% | -18,911 | -17,005 | -14,726 | -16,452 | -6,990 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 175.8% | 151 | 55.00 | 45.00 | 44.00 | 30.00 | 38.00 | 57.00 | 78.00 | 65.00 | 90.00 | 119 | 137 | 156 | 105 | 125 | 151 | 166 | 48.00 | 37.00 | 47.00 | 17.00 |
Current Assets | 177.5% | 151 | 54.00 | 44.00 | 43.00 | 29.00 | 37.00 | 56.00 | 77.00 | 64.00 | 88.00 | 117 | 135 | 154 | 103 | 123 | 149 | 164 | 46.00 | 37.00 | 47.00 | 17.00 |
Cash Equivalents | 193.6% | 146 | 50.00 | 37.00 | 36.00 | 23.00 | 17.00 | 40.00 | 56.00 | 38.00 | 54.00 | 70.00 | 78.00 | 84.00 | 57.00 | 49.00 | 101 | 93.00 | 19.00 | 13.00 | 41.00 | 15.00 |
Liabilities | 16.6% | 84.00 | 72.00 | 56.00 | 48.00 | 34.00 | 34.00 | 47.00 | 52.00 | 23.00 | 27.00 | 32.00 | 25.00 | 21.00 | 23.00 | 22.00 | 20.00 | 10.00 | 16.00 | 7.00 | 7.00 | 6.00 |
Current Liabilities | 17.9% | 84.00 | 71.00 | 56.00 | 47.00 | 33.00 | 33.00 | 47.00 | 52.00 | 22.00 | 26.00 | 31.00 | 23.00 | 20.00 | 21.00 | 21.00 | 19.00 | 8.00 | 14.00 | 7.00 | 7.00 | 6.00 |
Shareholder's Equity | 492.5% | 67.00 | -17.15 | - | - | -4.07 | 4.00 | 10.00 | 26.00 | 42.00 | 63.00 | 87.00 | 112 | 135 | 82.00 | 103 | 130 | 156 | 33.00 | 31.00 | 40.00 | - |
Retained Earnings | -17.9% | -552 | -468 | -430 | -388 | -358 | -348 | -334 | -315 | -289 | -266 | -239 | -210 | -184 | -160 | -137 | -107 | -79.14 | -66.77 | -49.14 | -38.42 | -29.99 |
Additional Paid-In Capital | 37.3% | 620 | 451 | 420 | 384 | 355 | 353 | 344 | 341 | 331 | 329 | 326 | 323 | 320 | 243 | 240 | 237 | 235 | 99.00 | 80.00 | 78.00 | 2.00 |
Shares Outstanding | 34.6% | 114 | 85.00 | 77.00 | 62.00 | 48.00 | 48.00 | 34.00 | 27.00 | 26.00 | 26.00 | 25.00 | 26.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 64.00 | - | - | - | 28.00 | - | - | - | 393 | - | - | - | 659 | - | - | - | 68.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -11.2% | -18,911 | -17,005 | -14,726 | -16,452 | -6,990 | -15,893 | -19,390 | -18,400 | -24,410 | -26,942 | -15,665 | -25,908 | -22,213 | -22,750 | -20,693 | -15,911 | -18,855 | -12,407 | -7,839 | -9,059 | -7,002 |
Share Based Compensation | 46.3% | 2,379 | 1,626 | 1,836 | 1,843 | 2,055 | 1,998 | 3,297 | 2,231 | 2,077 | 2,849 | 2,645 | 2,702 | 2,981 | 2,555 | 2,403 | 1,737 | 1,331 | 1,348 | 1,219 | 3,279 | 325 |
Cashflow From Investing | - | - | - | - | - | 13,872 | -6,905 | 5,021 | 5,529 | 9,525 | 11,807 | 8,518 | 16,780 | -24,672 | 28,444 | -30,246 | 24,044 | -41,711 | - | - | - | - |
Cashflow From Financing | 292.2% | 115,497 | 29,446 | 16,567 | 29,151 | -622 | -933 | -971 | 30,385 | -789 | -1,184 | -1,080 | 3,495 | 73,486 | 3,093 | -1,236 | 218 | 134,219 | 18,320 | -294 | 35,449 | 2,940 |
Condensed Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
REVENUE: | ||
Total revenue | $ 190 | $ 10,660 |
COSTS AND EXPENSES: | ||
Research and development | 12,217 | 15,935 |
General and administrative | 9,066 | 5,583 |
Total costs and expenses | 21,283 | 21,518 |
LOSS FROM OPERATIONS | (21,093) | (10,858) |
OTHER (EXPENSE) INCOME, NET: | ||
Interest income | 586 | 221 |
Change in fair value of warrant liabilities | (63,405) | 469 |
Other expense | (26) | 31 |
Total other (expense) income, net | (62,845) | 721 |
Net loss | $ (83,938) | $ (10,137) |
Net loss per share attributable to common stockholders-basic (in dollars per share) | $ (0.67) | $ (0.18) |
Net loss per share attributable to common stockholders-diluted (in dollars per share) | $ (0.67) | $ (0.18) |
Weighted-average common stock outstanding-basic (in shares) | 125,318,993 | 56,357,983 |
Weighted-average common stock outstanding-diluted (in shares) | 125,318,993 | 56,357,983 |
License | ||
REVENUE: | ||
Total revenue | $ 10,660 | |
Research and development services | ||
REVENUE: | ||
Total revenue | $ 190 |
Condensed Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 146,484 | $ 49,898 |
Security deposits and leasehold improvements | 253 | 254 |
Prepaid expenses and other current assets | 4,169 | 4,234 |
Total current assets | 150,906 | 54,386 |
Operating lease right-of-use asset | 328 | 447 |
TOTAL ASSETS | 151,234 | 54,833 |
CURRENT LIABILITIES: | ||
Current portion of operating lease liabilities | 308 | 429 |
Accounts payable | 4,019 | 1,742 |
Accrued expenses and other current liabilities | 14,641 | 15,286 |
Warrant liabilities | 64,937 | 53,725 |
Total current liabilities | 83,905 | 71,182 |
NONCURRENT LIABILITIES: | ||
Noncurrent portion of operating lease liabilities | 35 | 38 |
Clinical holdback - long-term portion | 759 | |
Total noncurrent liabilities | 35 | 797 |
Total liabilities | 83,940 | 71,979 |
STOCKHOLDERS' EQUITY/(DEFICIT): | ||
Common stock, $0.0001 par value; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 114,241,803 shares issued and outstanding as of March 31, 2024 and 84,869,832 shares issued and outstanding as of December 31, 2023 | 11 | 8 |
Preferred stock, par value $0.0001; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | ||
Additional paid-in capital | 619,807 | 451,432 |
Accumulated deficit | (552,524) | (468,586) |
Total stockholders' (deficit)/equity | 67,294 | (17,146) |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY/(DEFICIT) | $ 151,234 | $ 54,833 |